Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease

Mustafa CEYLAN, (Atatürk Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, Hareket Bozuklukları ve Nöromodülasyon Merkezi, Erzurum, Türkiye)
Murat GÜLTEKİN, (Erciyes Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, Kayseri, Türkiye)
Nazlı DURMAZ ÇELİK, (Osmangazi Üniversitesi, Tıp Fakültesi, Nöroloji Bölümü, Eskişehir, Türkiye)
Bedia SAMANCI, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Nöroloji Anabilim Dalı, Davranışsal Nöroloji ve Hareket Bozuklukları Birimi, İstanbul, Türkiye)
Gül YALÇIN ÇAKMAKLI, (Hacettepe Üniversitesi, Tıp Fakültesi, Nöroloji Bölümü, Ankara, Türkiye)
Rezzak YILMAZ (Ankara Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)
Eurasian Journal of Medicine
2 0
Yıl: 2022 Cilt: 54 Sayı: 1 Sayfa Aralığı: 71 - 76 Metin Dili: İngilizce DOI: 10.5152/eurasianjmed.2022.22134 İndeks Tarihi: 24-05-2023

Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease

Öz:
The intermittent subcutaneous injection of apomorphine is highly effective in the management of motor and non-motor symptoms of Parkinson’s disease. Although it has been shown that apomorphine injection can be safely used in selected cases at all stages of the disease, there is no consensus regarding intermittent administration strategies. This review aimed to discuss the indications for intermittent subcutaneous apomorphine use in clinical practice, possible side effects and their management, and contraindicated cases in light of the literature and to present practical recommendations for clinical practice.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Müller T. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease. Expert Opin Pharmacother. 2020;21(14):1659-1665. [CrossRef]
  • 2. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002;303(2):791-804. [CrossRef]
  • 3. Lees AJ. Dopamine agonists in Parkinson's disease: a look at apomorphine. Fundam Clin Pharmacol. 1993;7(3-4):121-128. [CrossRef]
  • 4. Schwab RS, Amador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc. 1951;56:251-253.
  • 5. Stibe C, Lees A, Stern G. Subcutaneous infusion of apomorphine and lisuride in the treatment of parkinsonian on-off fluctuations. Lancet. 1987;1(8537):871. [CrossRef]
  • 6. https ://ww w.acc essda ta.fd a.gov /drug satfd a_doc s/ nda /2004 /21-2 64_Ap okyn. cfm 7. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol. 2009;8(10):929-937. [CrossRef]
  • 8. Özkan S, Erer S, Elibol B, et al. Apomorphine in the treatment of Parkinson's disease. Turk J Neurol; 27(4):358-365. [CrossRef]
  • 9. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58(9):1385-1392. [CrossRef]
  • 10. Pfeiffer RF, Gutmann L, Hull KL Jr, Bottini PB, Sherry JH, Investigators APOS. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord. 2007;13(2):93-100. [CrossRef]
  • 11. Pahwa R, Koller WC, Trosch RM, Sherry JH, Investigators APOS. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci. 2007;258(1-2):137-143. [CrossRef]
  • 12. Isaacson S, Lew M, Ondo W, Hubble J, Clinch T, Pagan F. Apomorphine subcutaneous injection for the management of morning akinesia in Parkinson's disease. Mov Disord Clin Pract. 2017;4(1):78-83. [CrossRef]
  • 13. Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990;53(2):96-101. [CrossRef]
  • 14. Tolosa E, Marti MJ, Katzenschlager R. Pharmacologic management of Parkinson’s disease. In: Jankovic J, ed. Parkinson's Disease and Movement Disorders. 6th ed. Philadelphia: Wolters Kluwer; 2015:86-111.
  • 15. Wang L, Xiong N, Huang J, et al. Proteinrestricted diets for ameliorating motor fluctuations in Parkinson's disease. Front Aging Neurosci. 2017;9:206. [CrossRef]
  • 16. Trenkwalder C, Chaudhuri KR, García Ruiz PJ, et al. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease–Clinical practice recommendations. Parkinsonism Relat Disord. 2015;21(9):1023-1030. [CrossRef]
  • 17. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging. 2004;21(11):687-709. [CrossRef]
  • 18. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 2006;5(3):235-245. [CrossRef]
  • 19. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. 2012;72(4):587-598. [CrossRef]
  • 20. Ellis C, Lemmens G, Parkes JD, et al. Use of apomorphine in parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord. 1997;3(2):103-107. [CrossRef]
  • 21. van Laar T, Postma AG, Drent M. Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism Relat Disord. 2010;16(1):71-72. [CrossRef]
  • 22. Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol. 2011;258(4):579-585. [CrossRef]
  • 23. Borgemeester RW, Lees AJ, van Laar T. Parkinson's disease, visual hallucinations and apomorphine: a review of the available evidence. Parkinsonism Relat Disord. 2016;27:35-40. [CrossRef]
  • 24. Ray-Chaudhuri K, Abbott RJ, Millac PA. Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment. J Neurol Neurosurg Psychiatry. 1991;54(4):372-373. [CrossRef]
  • 25. Dafsari HS, Martinez-Martin P, Rizos A, et al. EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. Mov Disord. 2019;34(3):353-365. [CrossRef]
  • 26. Drapier S, Gillioz AS, Leray E, et al. Apomorphine infusion in advanced Parkinson’s patients with subthalamic stimulation contraindications. Parkinsonism Relat Disord. 2012;18(1):40-44. [CrossRef]
  • 27. Yarnall AJ, Lashley T, Ling H, et al. Apomorphine: a potential modifier of amyloid deposition in Parkinson's disease? Mov Disord. 2016;31(5):668- 675. [CrossRef]
  • 28. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson's disease. Brain Pathol. 2010;20(3):633-639. [CrossRef]
  • 29. Poletti M, Frosini D, Pagni C, et al. Mild cognitive impairment and cognitive-motor relationships in newly diagnosed drug-naive patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012;83(6):601-606. [CrossRef]
  • 30. Suttrup I, Warnecke T. Dysphagia in Parkinson's disease. Dysphagia. 2016;31(1):24-32. [CrossRef]
  • 31. Baijens LWJ, Speyer R. Effects of therapy for dysphagia in Parkinson's disease: systematic review. Dysphagia. 2009;24(1):91-102. [CrossRef]
  • 32. Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol. 1989;46(10):1061-1064. [CrossRef]
  • 33. Reuter I, Ellis CM, Ray Chaudhuri KR. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand. 1999;100(3):163-167. [CrossRef]
  • 34. Borgemeester RW, Drent M, van Laar T. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. Parkinsonism Relat Disord. 2016;23:17- 22. [CrossRef]
  • 35. Nomoto M, Kubo S, Nagai M, et al. A randomized controlled trial of subcutaneous apomorphine for Parkinson disease: a repeat dose and pharmacokinetic study. Clin Neuropharmacol. 2015;38(6):241-247. [CrossRef]
  • 36. Bhidayasiri R, Garcia Ruiz PJ, Henriksen T. Practical management of adverse events related to apomorphine therapy. Parkinsonism Relat Disord. 2016;33(suppl 1):S42-S48. [CrossRef]
  • 37. Skorvanek M, Bhatia KP. The skin and Parkinson's disease: review of clinical, diagnostic, and therapeutic issues. Mov Disord Clin Pract. 2017;4(1):21- 31. [CrossRef]
  • 38. Poltawski L, Edwards H, Todd A, Watson T, Lees A, James CA. Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. Mov Disord. 2009;24(1):115-118. [CrossRef]
  • 39. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry. 1998;65(5):709-716. [CrossRef]
  • 40. Jenner P, Katzenschlager R. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease. Parkinsonism Relat Disord. 2016;33(suppl 1):S13-S21. [CrossRef]
  • 41. Hagell P, Odin P. Apomorphine in the treatment of Parkinson's disease. J Neurosci Nurs. 2001;33(1):21-34. [CrossRef]
  • 42. García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130- 1136. [CrossRef]
  • 43. Grandas F. Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease. Expert Rev Neurother. 2013;13(12):1343-1353. [CrossRef]
  • 44. Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930-1933. [CrossRef]
  • 45. Venegas Pérez B, Arquero Portero T, Sánchez Fernández MS, Feliz Feliz C, Del Val Fernández J, García-Ruiz PJ. Apomorphine-induced immune hemolytic anemia. Mov Disord Clin Pract. 2017;4(1):145-147. [CrossRef]
APA Ceylan M, GULTEKIN M, Durmaz Çelik F, Samanci B, Yalcin Cakmakli G, Yılmaz R (2022). Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. , 71 - 76. 10.5152/eurasianjmed.2022.22134
Chicago Ceylan Mustafa,GULTEKIN MURAT,Durmaz Çelik Fatma Nazli,Samanci Bedia,Yalcin Cakmakli Gul,Yılmaz Rezzak Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. (2022): 71 - 76. 10.5152/eurasianjmed.2022.22134
MLA Ceylan Mustafa,GULTEKIN MURAT,Durmaz Çelik Fatma Nazli,Samanci Bedia,Yalcin Cakmakli Gul,Yılmaz Rezzak Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. , 2022, ss.71 - 76. 10.5152/eurasianjmed.2022.22134
AMA Ceylan M,GULTEKIN M,Durmaz Çelik F,Samanci B,Yalcin Cakmakli G,Yılmaz R Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. . 2022; 71 - 76. 10.5152/eurasianjmed.2022.22134
Vancouver Ceylan M,GULTEKIN M,Durmaz Çelik F,Samanci B,Yalcin Cakmakli G,Yılmaz R Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. . 2022; 71 - 76. 10.5152/eurasianjmed.2022.22134
IEEE Ceylan M,GULTEKIN M,Durmaz Çelik F,Samanci B,Yalcin Cakmakli G,Yılmaz R "Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease." , ss.71 - 76, 2022. 10.5152/eurasianjmed.2022.22134
ISNAD Ceylan, Mustafa vd. "Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease". (2022), 71-76. https://doi.org/10.5152/eurasianjmed.2022.22134
APA Ceylan M, GULTEKIN M, Durmaz Çelik F, Samanci B, Yalcin Cakmakli G, Yılmaz R (2022). Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. Eurasian Journal of Medicine, 54(1), 71 - 76. 10.5152/eurasianjmed.2022.22134
Chicago Ceylan Mustafa,GULTEKIN MURAT,Durmaz Çelik Fatma Nazli,Samanci Bedia,Yalcin Cakmakli Gul,Yılmaz Rezzak Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. Eurasian Journal of Medicine 54, no.1 (2022): 71 - 76. 10.5152/eurasianjmed.2022.22134
MLA Ceylan Mustafa,GULTEKIN MURAT,Durmaz Çelik Fatma Nazli,Samanci Bedia,Yalcin Cakmakli Gul,Yılmaz Rezzak Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. Eurasian Journal of Medicine, vol.54, no.1, 2022, ss.71 - 76. 10.5152/eurasianjmed.2022.22134
AMA Ceylan M,GULTEKIN M,Durmaz Çelik F,Samanci B,Yalcin Cakmakli G,Yılmaz R Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. Eurasian Journal of Medicine. 2022; 54(1): 71 - 76. 10.5152/eurasianjmed.2022.22134
Vancouver Ceylan M,GULTEKIN M,Durmaz Çelik F,Samanci B,Yalcin Cakmakli G,Yılmaz R Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease. Eurasian Journal of Medicine. 2022; 54(1): 71 - 76. 10.5152/eurasianjmed.2022.22134
IEEE Ceylan M,GULTEKIN M,Durmaz Çelik F,Samanci B,Yalcin Cakmakli G,Yılmaz R "Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease." Eurasian Journal of Medicine, 54, ss.71 - 76, 2022. 10.5152/eurasianjmed.2022.22134
ISNAD Ceylan, Mustafa vd. "Intermittent Subcutaneous Injections of Apomorphine in Parkinson’s Disease". Eurasian Journal of Medicine 54/1 (2022), 71-76. https://doi.org/10.5152/eurasianjmed.2022.22134
Sayfa Oluşturulma Tarihi
24-04-2024 7:23

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları